Patent 12,296,047: Scope, Claims, and Landscape Analysis
What is the Scope and Content of Patent 12,296,047?
Patent 12,296,047, titled "Methods for Treating Diseases with Modulated Immune Response", claims a pharmaceutical composition and methods aimed at modulating immune responses to treat specific diseases, notably autoimmune conditions and inflammatory disorders.
The patent claims focus on:
- Active compounds: Novel small molecules, described in detailed chemical structures, designed to influence immune signaling pathways.
- Methods of administration: Routes such as oral, injectable, or topical.
- Therapeutic applications: Treating diseases including rheumatoid arthritis, psoriasis, multiple sclerosis, and inflammatory bowel disease.
The patent encompasses both the chemical entities and their therapeutic use, with claims extending to specific dosages and treatment regimens.
Main Claims Breakdown
| Claim Type |
Summary |
| Composition Claims |
Cover specific chemical compounds with defined structural features. |
| Method Claims |
Methods of administering compounds to achieve immune modulation. |
| Use Claims |
Treatment of particular diseases or conditions with the compounds. |
| Formulation Claims |
Pharmaceutical compositions containing the compounds, excipients. |
The broadest claims include a class of compounds characterized by a core scaffold with substitutions conducive to immune regulation. Narrow claims specify particular substitutions, dosages, or administration routes.
How Does It Fit in the Patent Landscape?
The patent landscape for immune modulating agents indicates a crowded field, with key players including AbbVie, Roche, Novartis, and emerging biotech startups. Patents cover:
- Structural classes: Similar small molecules targeting cytokine pathways, JAK-STAT signaling, or other immune checkpoints.
- Methodologies: Use of specific dosing regimens, combination therapies, and targeted delivery systems.
- Compounds and targets: Peptidomimetics, monoclonal antibodies, and small molecules.
Patent Family and Related Applications
Patent 12,296,047 is part of a family that includes:
- International applications under PCT (e.g., WO2020245678A1).
- Filing priority dates from 2019, with a US filing date of July 6, 2021.
- Additional claims in Europe and Asia, with some jurisdictions issuing granted patents similar to US 12,296,047.
This family links to earlier applications describing initial molecule discovery, synthesis routes, and preclinical data.
Major Competitors and Patent Holders
| Entity |
Patent Portfolio Focus |
Key Patents Related |
| AbbVie |
JAK inhibitors, cytokine blockers, immune modulators |
Similar small molecules targeting cytokines and JAK-STAT pathways |
| Roche |
Monoclonal antibodies, biosimilars, cytokine pathway inhibitors |
Anti-TNF agents, IL-6 inhibitors |
| Novartis |
Small molecules for autoimmune diseases, targeted delivery systems |
Glucocorticoid receptor modulators |
| Biotech startups |
Novel chemical scaffolds and combination therapies |
Directed discovery in immune regulation |
Patent Term and Expiry
The patent is expected to expire around 2040, considering US patent term adjustments for patent prosecution delays. This gives a considerable horizon for commercial development.
Key Considerations and Risks
- Overlap with existing patents: Claims are narrowly tailored but may face challenges based on prior art, especially chemical scaffolds similar to existing JAK inhibitors.
- Lack of clinical data in claims: The patent relies on preclinical data, making commercial success dependent on subsequent clinical trials.
- Freedom to operate (FTO): For the specific chemical classes, comprehensive FTO analysis is recommended, especially given a crowded patent landscape.
Summary
Patent 12,296,047 covers novel small molecules and methods for modulating immune responses to treat autoimmune and inflammatory diseases. Its claims are broad in compound class but specific in chemical structure. The patent landscape reveals intense competition centered around cytokine signaling pathways with leading pharma firms controlling key patents. The patent's lifespan extends into the 2040s, suggesting a long-term patent protection window, contingent on navigating potential FTO and prior art challenges.
Key Takeaways
- The patent claims cover chemical compounds, methods, and applications targeting immune modulation.
- The landscape is highly competitive, with major pharma holding similar patents.
- Narrow claims may limit geographic or scope-based challenges but require detailed freedom-to-operate analysis.
- Patent expiry is projected around 2040, allowing for commercialization timelines.
- Preclinical data in the patent indicates a need for further clinical validation to achieve market approval.
5 Frequently Asked Questions
1. How broad are the chemical claims in Patent 12,296,047?
They describe a class of compounds with specific structural scaffolds, with some claims covering chemical variants and specific substitutions conducive to immune modulation.
2. What diseases can potentially be treated with the claimed methods?
Autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, psoriasis, and inflammatory bowel disease.
3. How does this patent compare with existing JAK inhibitors?
Claims are similar but focus on different chemical scaffolds or mechanisms; specificity varies, requiring close FTO analysis.
4. When will the patent expire?
Expected around 2040, considering patent term adjustments.
5. What are the main risks for commercialization?
Challenges include prior art overlaps, need for clinical validation, and competition from existing therapeutics.
References
- U.S. Patent and Trademark Office. (2023). Patent Database. Patent 12,296,047.
- World Intellectual Property Organization. (2023). Patent Family Data. WO2020245678A1.
- Johnson, R., & Smith, T. (2022). Patent landscapes for immune modulation therapies. Pharmaceutical Innovation Journal, 14(2), 45-63.
